Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul012009	Fate Therapeutics Granted Exclusive License by The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration La Jolla, CA – Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed Read All »	View HTML Fate Therapeutics Granted Exclusive License by The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration 10.6 KB
Toggle SummaryJul082009	Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway La Jolla, CA and Barcelona – Fate Therapeutics, Inc. announced today the presentation of data from its research on small molecule modulators of the Wnt pathway for Read All »	View HTML Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway 12.9 KB
Toggle SummaryOct182009	Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming Development of Two Week Method for Generating Human Induced Pluripotent Stem Cells with 200-Fold Increase in Yield Read All »	View HTML Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 11.2 KB
Toggle SummaryNov162009	Fate Therapeutics Closes $30 Million Series B Financing Led by OVP Venture Partners and Includes Syndicate of Corporate Investors Read All »	View HTML Led by OVP Venture Partners and Includes Syndicate of Corporate Investors 12.1 KB
Toggle SummaryDec212009	Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs San Diego, CA – Fate Therapeutics, Inc. announced today that the Company’s iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Read All »	View HTML Fate Therapeutics’ iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs 12.7 KB
Toggle SummaryFeb042010	Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology San Diego, CA – Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled “Methods for Reprogramming Somatic Cells.” Upon issuance, the patent will cover foundational induced Read All »	View HTML Fate Therapeutics Receives Allowance of First U.S. Patent for Induced Pluripotent Stem Cell Technology 12.6 KB
Toggle SummaryFeb262010	Fate Therapeutics Named One of the 50 Most Innovative Companies in the World By MIT's Technology Review San Diego, CA – Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review’s 2010 TR50 , the first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and Read All »	View HTML Fate Therapeutics Named One of the 50 Most Innovative Companies in the World By MIT’s Technology Review 11.9 KB
Toggle SummaryApr082010	Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Read All »	View HTML Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics 12.6 KB
Toggle SummaryMay102010	Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of Tom Novak, Ph.D., as vice president of research and drug discovery. Dr. Novak brings to Fate more than 15 years of experience working with large pharmaceutical companies, including Roche and Wyeth, to Read All »	View HTML Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 10.2 KB
Toggle SummaryMay112010	Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company’s Scientific Advisory Board (SAB). The new SAB members bring deep experience and expertise in systems biology, epigenetics, gene regulation, expression Read All »	View HTML Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline 12 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.